SUMMIT THERAPEUTICS INC (SMMT)
NASDAQ • Healthcare
$12.82
+$0.04 (+0.3%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About SUMMIT THERAPEUTICS INC
Name
SUMMIT THERAPEUTICS INC
CEO
Robert W. Duggan
Website
Industry
Healthcare
Year Founded
2003
Employees
265
Summit Therapeutics Inc. is a NASDAQ-listed biotechnology company focused on discovering, developing, and commercializing therapeutic solutions. In qualitative terms, it is a clinical-stage healthcare business built around anti-infective drug development, with a pipeline centered chiefly on Clostridioides difficile infection, or CDI, including the Phase III program ridinilazole.
Fundamentals & Financials
Revenue (TTM)
$0
Net Income (TTM)
-$856M
EPS (TTM)
-$1.12
ROA (TTM)
-113.81%
Current Ratio
6.96
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$12.82$12.53 - $13
52 Week RangeAvg. Volume$12.07 - $30.054.6M
Market Cap$10.2B
Peers & Related Assets
RVMDREVOLUTION MEDICINES INC
$216+1.9%
ROIVROIVANT SCIENCES LTD
$37.37+3.1%
RPRXROYALTY PHARMA PLC CLASS A
$59.69+0.4%
MRNAMODERNA INC
$62.96-2.3%
BBIOBRIDGEBIO PHARMA INC
$82.98+3.9%
UHSUNIVERSAL HEALTH SERVICES INC CLAS
$173.09+1.5%
IONSIONIS PHARMACEUTICALS INC
$59.62+1.7%
EXASExact Sciences Corporation
ASNDAscendis Pharma A/S
RNAATRIUM THERAPEUTICS INC